
Proportion of population received booster in evidence source setting & 0.386  & Assumed \\ 
\hline
Proportion of population received two doses but no booster & 0.302  & Assumed \\ 
\hline
Proportion of population not received primary course & 0.312  & Assumed \\ 
\hline
Protection against severe disease from booster assumed for evidence source setting & 0.85  & Assumed \\ 
\hline
Protection against severe disease from primary course for evidence source setting & 0.5  & Assumed \\ 
\hline
Relative infectiousness of asymptomatic persons & 0.5  & Assumed \\ 
\hline
Duration of booster effect & 90 days & Assumed \\ 
\hline
Probability of transmission per contact & 0.362  & Assumed \\ 
\hline
Distribution type for hospital stay & gamma  & Assumed \\ 
\hline
Mean hospital stay & 3.0 days & Assumed \\ 
\hline
Shape parameter for hospital stay & 5.0  & Assumed \\ 
\hline
Distribution type for ICU stay & gamma  & Assumed \\ 
\hline
Mean ICU stay & 4.7 days & Assumed \\ 
\hline
Shape parameter for ICU stay & 5.0  & Assumed \\ 
\hline
Reduction in transmission risk for boosted & 0.6  & Assumed \\ 
\hline
Reduction in transmission risk for primary course & 0.4  & Assumed \\ 
\hline
Starting infectious seed & 249.0 persons & Assumed \\ 
\hline
Relative infectiousness of isolated cases & 0.2  & Assumed \\ 
\hline
Proportion of hospitalised persons admitted to ICU & 0.08  & Assumed \\ 
\hline
ISO3 code for source country for mixing matrix & CHN  & Assumed \\ 
\hline
Proportion of active period before isolation & 0.333  & Assumed \\ 
\hline
Relative infectiousness of isolated cases & 0.2  & Assumed \\ 
\hline
Index testing rate (\(tests(t)\)) & 0.0001 tests per day & Assumed \\ 
\hline
CDR reached at index testing rate (\(CDR(t)\)) & 0.0615  & Assumed \\ 
\hline
CDR floor (\(floor\)) & 0.06  & Assumed \\ 
\hline
Interval for moving average of daily tests & 14 days & Assumed